Ambrx Appoints Gary Yeung as Main Economical Officer and Chief Working Officer

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — Ambrx Inc. nowadays introduced the appointment of Gary Yeung, CFA, MBA, as Chief Fiscal Officer and Chief Operating Officer. Mr. Yeung brings considerable leadership working experience in boosting money, making biotech providers, and foremost organizations to create novel therapeutics.

“Ambrx is at a critical inflection place to progress our pipeline of Engineered Precision Biologics pursuing our recent $200M private funding round. Gary’s robust observe report of boosting funds and developing teams that assistance the advancement of breakthrough medications is well timed,” mentioned Dr. Feng Tian, Chairman, President and CEO. “Gary’s abilities and leadership expertise in finance, drug growth, technique, portfolio management, and operations uniquely situation him to provide sizeable impact to our coming progress phases.”

“I am passionate about working with firms that can adjust patients’ life. Dr. Tian and his team have been the pioneers and innovators of the expanded genetic code technological innovation employing web-site-unique incorporation of artificial amino acids into proteins to generate drug candidates that are on the cusp of demonstrating the breakthrough nature of its system. In unique, I am enthusiastic about ARX788’s modern Speedy Monitor Designation by the FDA and its likely to be the ideal-in-course, following-technology, anti-HER2 ADC based on my encounter of producing and commercializing HER2 goods,” explained Mr. Yeung. “I glance forward to partnering with the administration staff and the board to mature the firm and produce novel Engineered Precision Biologics to patients.”

Mr. Yeung joins Ambrx from Erasca, in which he served as CFO & COO assisting finance the organization and advance various compounds into clinical trials. Prior to Erasca, Mr. Yeung helped construct two biotech businesses, Guardant Wellness and Annexon Biosciences. At Guardant, he was vice president of the early most cancers detection organization and a member of the management team. At Annexon, Mr. Yeung served as vice president of company and growth operations. He also devoted 12 many years at Genentech, creating organizations to establish and start ground breaking therapies. He oversaw the portfolio and job management features that developed 42 INDs and formulated various Fda-permitted treatment options, which include Tecentriq and Venclexta. He also held leadership roles in finance and industrial operations to assist the start and enlargement of the Immunology and BioOncology franchises. Previously in his job, Mr. Yeung was a guide with McKinsey and an operational chief with GE. He holds a B.S. in chemical engineering from the College of California, Berkeley, and an MBA from UCLA. He is a Chartered Economical Analyst (CFA).&#13

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical corporation employing an expanded genetic code to generate Engineered Precision Biologics, this features upcoming technology antibody drug conjugates (ADCs), bispecifics, and focused immuno-oncology therapies for most cancers as well as novel cytokines to modulate the immune system and prolonged-performing therapeutic peptides for metabolic and cardiovascular ailment, all designed to have enhanced pharmacologic properties and novel organic exercise. Leveraging the Ambrx proprietary know-how platforms, Ambrx has collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, with drug solutions created working with Ambrx technologies in different stages of scientific trials. Ambrx is advancing a robust portfolio of medical and preclinical plans optimized for efficacy, safety and relieve of use in a number of therapeutic places. For added details, check out www.ambrx.com.

Contact:
Amy Conrad
858-366-3243
[email protected]

See initial written content to obtain multimedia:https://www.prnewswire.com/information-releases/ambrx-appoints-gary-yeung-as-chief-economical-officer-and-main-running-officer-301202615.html